In August 2011, the Company entered into a non-cancelable operating lease for combined office and manufacturing facilities in Mountain View, California. The lease was scheduled to expire in April 2019 and was amended in May 2018 to extend it through June 2024. In August 2022, the Company amended the lease to extend it through June 2030. The second amendment contained a rent-free period from September 2022 through December 2022. The Company has an option to extend the lease for a period of five years, commencing on July 1, 2030 and expiring on June 30, 2035. The renewal terms have not been included in the lease term used to calculate the ROU assets and lease liability as it is not reasonably certain that the Company will exercise the option. In conjunction with the original lease agreement, the Company obtained a letter of credit for $0.9 million in lieu of a security deposit. In May 2019, the letter of credit was amended and reduced to $0.7 million. In June 2021, the letter of credit was amended and further reduced to $0.2 million.

The terms of the facility lease provide for rental payments on a graduated scale; however, rent expense is recognized on a straight-line basis over the lease term. Rental payments range from $2.8 million to $3.3 million per year over the extended term of the lease.


(in thousands)	December 31, 2025
2026	$	3,031
2027	3,122
2028	3,215
2029	3,312
2030	1,704
Total undiscounted lease payments	14,384
Less: imputed interest	2,431
Total operating lease liability	11,953
Less: current portion	2,117
Operating lease liability, net of current portion	$	9,836

Operating lease cost was $2.8 million for each of the years ended December 31, 2025 and 2024. As of December 31, 2025, the remaining term for the operating lease in Mountain View, California was 4.5 years, and the discount rate used to measure the lease liability for such operating lease upon recognition was 8.5%.

During each of the years ended December 31, 2025 and 2024, cash paid for amounts included in operating lease liabilities of $2.9 million was included in cash flows from operating activities on the statements of cash flows.

In August 2022, the Company entered into an exclusive distribution agreement, or the Distribution Agreement, with DIXI Medical USA Corp, or DIXI Medical, pursuant to which the Company became the exclusive U.S. distributor of DIXI Medical’s stereo electroencephalography product line. The Distribution Agreement had an initial term of three years, which expired on September 30, 2025. During the initial term, to maintain the distribution rights, the Company was required to purchase a minimum of $2.4 million of DIXI Medical’s products during the twelve months beginning October 2022, and to increase the minimum purchase by 10% for each of the two subsequent years. The Company met the purchase commitment for every year of the Distribution Agreement.

The Distribution Agreement would have automatically renewed for additional one-year term, if neither party provided written notice to the other party of its intention to not renew at least 180 days prior to the expiration of the then-current term.

In March 2025, the Company notified DIXI Medical of its intent to not renew the Distribution Agreement upon expiration and, as a result, the Distribution Agreement terminated on September 30, 2025. The Distribution Agreement included a wind-down period following the termination date during which the Company had the right to sell any DIXI product inventory that it held on the date of expiration. At the end of the wind-down period, DIXI Medical is required to buy back, at cost, any DIXI product inventory with at least six months remaining shelf life held by the Company.

In December 2025, the Company and DIXI Medical entered into an amendment to the Distribution Agreement to end the wind-down period and cease commercial partnership activities on December 31, 2025. Under the amended wind-down plan, the Company is currently selling back, at cost, the remaining DIXI inventory to DIXI Medical, which is expected to be completed prior to the close of the first quarter of 2026. As of December 31, 2025, the Company had $2.0 million related to the DIXI product inventory.

In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and may provide for indemnification of the counterparty. The Company’s exposure under these agreements is unknown because it involves claims that may be made against it in the future but have not yet been made. The Company may, from time to time, be subject to claims or be required to defend actions related to its indemnification obligations.

The Company indemnifies each of its directors and officers for certain events or occurrences, subject to certain limits, while the director or officer is or was serving at the Company’s request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws. The term of the indemnification period lasts as long as the director or officer may be subject to any proceeding arising out of acts or omissions of such individual in such capacity. The maximum amount of potential future indemnification is unlimited. The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations as of December 31, 2025 and 2024.

From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. The Company determined that no accrual related to contingencies was required as of December 31, 2025 and 2024.

The Company is not involved in any pending legal proceedings that it believes could have a material adverse effect on its business, results of operations, financial condition, or cash flows. From time to time, the Company may

pursue litigation to assert its legal rights and such litigation may be costly and divert the efforts and attention of its management and technical personnel which could adversely affect its business. The Company regularly evaluates current information to determine whether any accruals should be adjusted and whether new accruals are required. Such accruals, if any, reflect the estimable and probable costs that the Company may incur from the outcomes of its legal proceedings. Legal costs are expensed as incurred. There were no material contingent liabilities requiring accrual as of December 31, 2025 and 2024.